IBX
IMAGION BIOSYSTEMS LIMITED
$0.0070
▲ +16.67%
Market cap
$6M
Turnover
$33,855
Last price
$0.0070
Day change
+16.67%
Announcements
10
Range, past year
Open 0.032 · Low 0.006 · Now 0.007 · High 0.055
Open IBX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
IBX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
25/100
Wyckoff phase
Accumulation17d
Trend stage
Neutral
1 Day
+16.7%
1 Week
+0.0%
1 Month
-12.5%
1 Year
-79.4%
RSI
45
Avg daily range
11.1%
IMAGION BIOSYSTEMS LIMITED scores 25 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 17 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.90 — highly linear uptrend
Points to watch
- 60d drawdown -53.8%
- High volatility (ATR 11.1%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
IBX announcements
Recent price-sensitive releases.
- 2026-10-08 Appendix 4C and Quarterly Activities Report - September 2026 Commitments Test Entity - Third Quarter Activity Report | Commitments Test Entity - Third Quarter Cashflow Report
- 2026-09-30 IBX Secures Central Ethics Approval - Key Phase 2 Milestone Progress Report
- 2026-09-14 MagSense Nanoparticle Manufacturing Update Progress Report
- 2026-08-26 IBX Phase 2 Clinical Trial Update Progress Report
- 2026-08-24 Appendix 4D and Half-yearly Financial Report Half Yearly Report | Half Year Audit Review | Half Year Directors' Statement | Half Year Accounts | Half Year Directors' Report
- 2026-07-31 Appendix 4C and Quarterly Activities Report - June 2026 Commitments Test Entity - Second Quarter Activity Report | Commitments Test Entity - Second Quarter Cashflow Report
- 2026-06-25 IBX Secures Firm Commitments for $3.75m for Clinical Trial
More Health Care stocks
Most traded in the same sector.